Evidence map›Paper›PMID 37987917›Full record

ReviewAdvances in therapy2024

Optimising Radioligand Therapy for Patients with Gastro-Entero-Pancreatic Neuroendocrine Tumours: Expert Opinion from an Italian Multidisciplinary Group.

Nicola Fazio, Massimo Falconi, Emanuela Foglia, Mirco Bartolomei, Alfredo Berruti, Mirko D'Onofrio, Diego Ferone, Alessandro Giordano, Franco Grimaldi, Massimo Milione and 7 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Advances in therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Nicola Fazio *Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, Istituto Europeo di Oncologia (IEO) IRCCS, Milan, Italy.ORCID 0000-0001-6869-0704
Massimo Falconi *Pancreatic Surgery Unit, Pancreas Translational & Clinical Research Center, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.ORCID 0000-0001-9654-7243
Emanuela Foglia *School of Industrial Engineering and HD LAB-Carlo Cattaneo-LIUC University, Castellanza, Italy.ORCID 0000-0003-1381-9069
Mirco BartolomeiNuclear Medicine Unit, Azienda Ospedaliero-Universitaria di Ferrara, Ferrara, Italy.ORCID 0000-0002-6474-4143
Alfredo BerrutiMedical Oncology Unit, ASST Spedali Civili, Brescia, Italy.ORCID 0000-0002-3956-0043
Mirko D'OnofrioRadiology, GB Rossi University Hospital, University of Verona, Verona, Italy.ORCID 0000-0003-3229-9329
Diego FeroneEndocrinology, Department of Internal Medicine and Medical Specialties (DiMI), University of Genova and Endocrinology Clinic, IRCCS, Ospedale Policlinico San Martino, Genoa, Italy.ORCID 0000-0002-1410-6143
Alessandro GiordanoNuclear Medicine Unit, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.ORCID 0000-0002-6978-0880
Franco GrimaldiEndocrinology and Diseases of Metabolism Unit, University Hospital Santa Maria Misericordia, Udine, Italy.ORCID 0000-0002-7527-8010
Massimo MilioneAnatomia Patologica 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.ORCID 0000-0002-1202-139X
Francesco PanzutoDepartment of Medical-Surgical Sciences and Translational Medicine, Sapienza University and Digestive Disease Unit, Sant'Andrea University Hospital, ENETS Center of Excellence, Rome, Italy.ORCID 0000-0003-2789-4289
Monica SantimariaNuclear Medicine Unit, S. Bortolo Hospital, AULSS 8 Berica, Vicenza, Italy.ORCID 0000-0002-2261-2230
Orazio SchillaciDepartment of Biomedicine and Prevention, University Tor Vergata, Rome, Italy.ORCID 0000-0002-6176-2805
Ettore SeregniNuclear Medicine Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.ORCID 0000-0002-5097-049X
Michele StasiMedical Physics Department, A.O. Ordine Mauriziano di Torino, Turin, Italy.ORCID 0000-0003-1294-0967
Marco VolanteDepartment of Oncology, University of Turin, and Pathology Unit, San Luigi Hospital, Turin, Orbassano, Italy.ORCID 0000-0003-0719-105X
Secondo LastoriaNuclear Medicine and Therapy with Radionuclides, Cyclotron and Radiopharmacy Units, IRCCS National Cancer Institute, Fondazione Senatore G. Pascale, Via M. Semmola, 80131, Naples, Italy. s.lastoria@istitutotumori.na.it.ORCID 0000-0002-6649-9903

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Radioligand therapy (RLT) with lutetium (

Indexed as

Liver NeoplasmsNeuroendocrine TumorsPancreatic NeoplasmsHumansSomatostatinSomatostatinDiagnostic–therapeutic care pathwayExpert opinionGastro-entero-pancreatic neuroendocrine tumoursItalyLutetium (177Lu) oxodotreotideOrganizational implications, radioligand therapy

Identifiers

PMID37987917
PMCPMC10796590

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.